Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

NCT00303615 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low accrural

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Fluoxymesterone 10 mg
DRUG: Anastrozole 1 mg

Sponsor

Legacy Health System